Advertisement

Topics

Japan's MHLW approves Olumiant to treat rheumatoid arthritis

05:39 EDT 4 Jul 2017 | Pharmaceutical Business Review

Eli Lilly and Company and Incyte announced that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies.

Original Article: Japan's MHLW approves Olumiant to treat rheumatoid arthritis

NEXT ARTICLE

More From BioPortfolio on "Japan's MHLW approves Olumiant to treat rheumatoid arthritis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...